Kangmei Pharmaceutical increased the amount of litigation of 1 billion, and the semi -annual performance disclosure was about 900 million in the first half of the year

Recently, ST Kangmei (600518.SH) announced the amount of recent cumulative lawsuits (arbitration), totaling 1.06 billion yuan.

The Red Star Capital Bureau noticed that the most involved amount involved in the case was Zhongrong Life Insurance Co., Ltd. (hereinafter referred to as "Zhongrong Life Insurance") and Guangfa Securities Co., Ltd. (hereinafter referred to as "Guangfa Securities")/(third person) ST Kangmei's bond transaction disputes reached 540 million yuan.

In addition, after the amount of the amount involved in the lawsuit (arbitration) was announced, ST Kangmei issued a pre-loss announcement for the semi-annual performance in 2022. It is expected that the net profit of the mother is -93 million yuan.

Cumulative litigation (arbitration) amount exceeds 1 billion

The pre -losses in the first half of the year are about 900 million

The follow -up lawsuit of the Kangmei case has not yet ended. According to its recent disclosure, the amount involved has reached 1.06 billion yuan.

As of July 13, ST Kangmei and subordinate companies have recently cumulative litigation (arbitration) of 1.06 billion yuan, exceeding 10%of the company's recent audit net assets absolute value. Among them, the amount of lawsuits (arbitration) actively prosecuted by the company and subordinate companies totaling a total of 5.243 million yuan, and the amount of litigation (arbitration) of passive prosecution (arbitration) of the company and subordinate companies totaling 1.05 billion yuan.

The Red Star Capital Bureau noticed that these cases involved contract disputes, damage to shareholders' interests, trading contract disputes, construction engineering disputes, third -party mortgage contract disputes, false statement of securities, and financial loan disputes.

In this regard, ST Kangmei said that because some cases have not yet opened, the judgment is being judged or has not yet been implemented, the company is currently unable to determine the impact on the company's current profit or post -period profit, and the specific impact shall prevail.

After the amount involved in the lawsuit (arbitration) was announced, ST Kangmei issued the announcement of the pre -loss announcement of the semi -annual performance in 2022. It is expected that the net profit attributable to the mother will be -930 million yuan, and the non-net profit will be -11.59 billion yuan.

Regarding the cause of losses, ST Kangmei explained that one was affected by the epidemic in the first half of 2022, especially in Shanghai and other cities. The chain investment layout is wide and fixed costs such as fixed costs are relatively high. The company's existing business scale and profitability are still in the process of recovery and have not yet reached expectations. Third, the prices of raw materials for traditional Chinese medicinal materials in the first half of this year generally rose, and the sales price is relatively stable, resulting in the relatively stable sales price, resulting in the relatively stable sales price, resulting in the relatively stable sales price, resulting in the relatively stable sales price, resulting in the relatively stable sales price, resulting in the relatively stable sales price, resulting in the relatively stable sales price, resulting in the relatively stable sales price, resulting in the relatively stable sales price, resulting in the relatively stable sales price, resulting in the relatively stable sales price, resulting in the relatively stable sales price, resulting in the relatively stable sales price, resulting in the relatively stable sales price, resulting in the relatively stable sales price, resulting in the relatively stable sales price, resulting in the relatively stable sales price, which caused the sales price The profitability of traditional Chinese medicine decoction has been affected.

Guangfa Securities is trapped in 500 million debt disputes

The Red Star Capital Bureau noticed that in the above 48 disputes, the most involved amount of the case, Zhongrong Life Insurance and Guangfa Securities/(third person) ST Kangmei's bond transaction disputes reached 540 million yuan.

In other words, the cumulative 1.06 billion yuan lawsuit (arbitration) involved the case involved, and more than half of the case came from Guangfa Securities. The dispute between the bond transaction showed that Zhongrong Life Insurance requested that Guangfa Securities/(third person) ST Kangmei compensation securities false statement lost 540 million yuan. The case was in a state of judgment.

In addition, the Hongxing Capital Bureau also noticed that, as the plaintiff, Guangfa Gan and Investment Co., Ltd. requested to confirm that the claims such as ST Kangmei and other respondents such as convertible bond funds were 360 ​​million yuan, and the auction case involved a guarantee of real estate.

Tianyancha APP shows that Guangfa Ganhe Investment Co., Ltd. is a wholly -owned subsidiary of Guangfa Securities, and ST Kangmei's sponsors who listed on the market were Guangfa Securities.

Red Star News reporter Deng Lingyao

Edit Yang Cheng

- END -